Business Context and Reporting Period
This Form 6-K filing by Cellyan Biotechnology Co., Ltd. covers the month of January 2026. The report addresses a regulatory notification received from The Nasdaq Capital Market regarding the listing status of the Company's Class A Ordinary Shares (trading symbol: HKPD).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on compliance with Nasdaq listing rules rather than financial performance.
Material Changes
The primary material change is the receipt of a deficiency notice from Nasdaq on January 12, 2026. The Company's Class A Ordinary Shares failed to meet the minimum closing bid price requirement of $1.00 for 30 consecutive business days. This deficiency does not result in immediate delisting, and trading continues uninterrupted.
Guidance, Outlook, and Risks
- Compliance Period: The Company has 180 calendar days, until July 13, 2026, to regain compliance. Compliance is achieved if the closing bid price remains at or above $1.00 for 10 consecutive business days.
- Contingency Plan: If compliance is not met by July 13, 2026, the Company may be eligible for an additional 180-day grace period. This requires meeting all other initial listing standards (excluding bid price) and potentially effecting a reverse share split.
- Reverse Share Split: If a reverse share split is chosen to cure the deficiency, it must be completed no later than 10 business days prior to July 13, 2026.
- Risk: Failure to regain compliance or qualify for a grace period could result in delisting from the Nasdaq Capital Market.
Investor Verification Checklist
- Verify the current trading price of HKPD to assess the likelihood of meeting the $1.00 bid price requirement within the 180-day window.
- Monitor for any announcements regarding a potential reverse share split before the July 13, 2026 deadline.
- Review the press release filed as Exhibit 99.1 for additional management commentary on the bid price deficiency.
- Confirm whether the Company meets the market value of publicly held shares requirement, which is necessary for the potential second grace period.